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three cases of other (undefi ned) glomerular 
disease. MGN as a potential etiologic link 
with IgG4-related systemic disease is 
intriguing because idiopathic MGN is also 
an IgG4-dominant disease, such that these 
may have a common pathogenetic link. 
 IgG4 itself is an unusual antibody and 
has some unusual physical characteristics. 
It is the rarest IgG subclass in the circula-
tion of normal individuals. Elevated titers 
of IgG4 are found in conditions of chronic 
antigen exposure; beekeepers, for exam-
ple, show elevated IgG4 directed against 
bee venom, and patients undergoing 
allergen immunotherapy develop 
increased IgG4 titers against the allergen. 
Compared with IgG1, the IgG4  molecule 
has weaker interchain disulfi de bridges, 
so that immunoglobulin half-molecules, 
composed of one heavy chain and one 
light chain, dissociate from each other. 
Once these dissociate, an IgG4 half-mol-
ecule may reassociate with another half-
molecule with specifi city for a diff erent 
antigen. 7,8 When IgG4 encounters anti-
gen, it can only form small, and presum-
ably harmless, immune complexes and 
may block antigen binding by the more 
pathogenic IgG1. IgG4 is also unable to fi x 
complement. In these ways, IgG4 is 
thought to act as an anti-infl ammatory 
molecule that can temper the immune 
response, at least in some circumstances. 
 While IgG4 is an  ‘ anti-inflammatory ’ 
immunoglobulin, it is perplexing that it is 
found to be increased in some disease states, 
most notably IgG4-related systemic disease. 
Th e mechanism of this disease and its asso-
ciation with IgG4 is unclear. IgG4 class 
switching depends on interleukin-4 and/or 
interleukin-13 mainly secreted by T-helper 
2 cells. Th ese are the same cytokines that 
promote an IgE response, although IgG4 
antibody may be present in the absence of 
IgE antibody against a particular antigen. 
Interleukin-10 (IL-10) has an eff ect on IgG4 
versus IgE class switching 9 and may be 
required for IgG4 class-switched B cells to 
diff erentiate into IgG4-secreting plasma 
cells. One may speculate that, in IgG4-
related systemic disease, an initial insult and 
process involving production of anti-
infl ammatory cytokines, including IL-10 
and tumor necrosis factor-  α , along with 
fi brogenic IL-13, drives increased fi brosis, 
induction of IgG4 class-switched B cells, 
and production and massive expansion of 
IgG4-secreting plasma cells. 
 TIN is a disease pattern with heteroge-
neous causes, both immune and nonim-
mune. Th e clinical presentation, laboratory 
results, and biopsy features are all consid-
ered to make a specifi c diagnosis. Th rough 
the work of Saeki  et al. , 3 we now have a 
clearer view of the clinicopathologic fea-
tures of a specifi c type of TIN that is part 
of systemic IgG4-related disease, which in 
turn will aid pathologists and clinicians in 
recognizing and offering appropriate 
treatment for this disease. 
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 Within the past few years, it has become 
apparent that fi broblastic growth factor 23 
(FGF23), a bone-derived phosphaturic 
hormone, plays a central role in the physio-
logical regulation of mineral and vitamin D 
metabolism. FGF23 induces urinary 
phosphate excretion by supp ress ing the 
expression of the sodium-phosphate 
cotransporter. FGF23 also suppresses the 
synthesis of 1,25-dihydroxyvitamin D 
[1,25(OH) 2 D] via inhibition of 1  -
hydroxylase and stimulation of 24-
hydroxylase. 1 Th ese eff ects are dependent 
on the presence of Klotho, which  converts 
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ubiquitous FGF receptor 1 (FGFR1) into 
a specifi c receptor for FGF23. 2,3 
 Th e identifi cation and characterization 
of FGF23 have reshaped our understand-
ing of the pathogenesis of secondary 
hyperparathyroidism (SHPT) in chronic 
kidney disease (CKD). 4 In these patients, 
circulating FGF23 levels increase progres-
sively as kidney function declines, 5,6 pre-
sumably to maintain neutral phosphate 
balance by promoting urinary phosphate 
excretion. However, this compensation 
results in the suppression of renal 
1,25(OH) 2 D production and thereby trig-
gers the early development of SHPT. In 
early-stage CKD, chronic PTH secretion 
results in the proliferation of parathyroid 
cells, initially leading to diff use hyperpla-
sia. In advanced CKD, some cells prolifer-
ate vigorously and form small nodules. 
Th ese nodules then enlarge grossly and 
become encapsulated, leading to nodular 
hyperplasia. Of note, both the calcium-
sensing receptor (CaSR) and vitamin D 
receptor (VDR) are progressively down-
regulated in the course of parathyroid 
hyperplasia, 7,8 which is believed to explain 
the resistance to active vitamin D therapy 
in advanced SHPT. 
 Th e parathyroid gland also expresses 
both Klotho and FGFR1, whereby FGF23 
acts directly to decrease PTH secretion 
and PTH mRNA. 9,10 However, in uremic 
patients undergoing dialysis, PTH secre-
tion remains elevated despite extremely 
high FGF23 levels. Recent data suggest 
that this parathyroid resistance to FGF23 
may be caused by decreased expression 
of the Klotho-FGFR1 complex in the 
parathyroid gland, 11 analogous to the 
downregulation of CaSR and VDR in 
hyperplastic parathyroid glands. 7,8 
Support for this hypothesis is provided by 
recent animal studies showing that the 
expression of both Klotho and FGFR1 was 
decreased in the parathyroid glands of 
CKD rats and that FGF23 failed to inhibit 
PTH secretion in both  in vitro cultures of 
parathyroid cells from CKD rats and 
 in vivo CKD rats. 12,13 
 In line with these investigations, Krajisnik 
 et al. 14 demonstrated similar phenotypic 
alterations in the expression of the par-
athyroid Klotho-FGFR1 complex among 
patients who received kidney transplants. 
Having analyzing the expression of Klotho 
and FGFR1 in 88 hyperplastic parathyroid 
glands from 10 end-stage CKD patients 
and 21 kidney transplant recipients, they 
found that these expressions were signifi -
cantly reduced compared with normal 
parathyroid tissues. And the downregula-
tion of parathyroid Klotho-FGFR1 com-
plex correlated signifi cantly with a decline 
in glomerular fi ltration rate, suggesting 
that the expression of parathyroid Klotho-
FGFR1 complex decreases progressively 
during the course of CKD. 
 Although these data correspond with 
the fi ndings of recent animal studies, 12,13 
the results of this study should be inter-
preted with caution. It is well known 
that even aft er successful kidney trans-
plantation, persistent hyperparathy-
roidism can occur, requiring surgical 
parathyroidectomy. Whether parathy-
roid hyperplasia persists or regresses in 
this setting may depend on its pattern of 
hyperplasia; diffuse hyperplasia may 
have a tendency for regression, whereas 
nodular hyperplasia is unlikely to 
regress. 15 In this regard, one should be 
aware that the study by Krajisnik  et al. 14 
comprised kidney transplant recipients 
with severe parathyroid hyperplasia, 
which would be a carryover from a pre-
transplant period with uremia. Th us the 
severity of SHPT in these patients is 
likely to be considerably diff erent from 
that in patients with nontransplant CKD 
with similar renal function. 
 Another issue that should be addressed 
is the complexity of disturbed mineral 
metabolism in kidney transplant recipi-
ents. Hypophosphatemia and inappropri-
ately low 1,25(OH) 2 D levels are common 
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 Figure 1  |  Progression of parathyroid hyperplasia in chronic kidney disease (CKD) and its possible regression after kidney transplantation. 
In early-stage CKD, parathyroid cells begin to proliferate, leading to diffuse hyperplasia. In end-stage CKD, some cells proliferate vigorously, forming 
small nodules. When these nodules enlarge grossly and become encapsulated, they constitute nodular hyperplasia. In the most severe cases, one of these 
nodules may occupy the entire gland (single nodule). During the course of parathyroid hyperplasia, the parathyroid expression of the Klotho-FGFR1 
complex is progressively downregulated. After successful kidney transplantation, diffuse hyperplasia may have a tendency to regress, but nodular 
hyperplasia is unlikely to do so. Whether upregulation of parathyroid Klotho-FGFR1 complex can occur after kidney transplantation and whether this 
would result in the attenuation of parathyroid hyperplasia remains to be elucidated. FGFR1, fibroblastic growth factor receptor 1. 
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complications after successful kidney 
transplantation. Recent studies suggest 
that this syndrome is attributable to per-
sistently elevated FGF23, which promotes 
phosphaturia and inhibits 1,25(OH) 2 D 
synthesis in the kidney allograft . 16 It is also 
suggested that some immunosuppressive 
agents may modulate mineral and vitamin 
D metabolism in these patients. Although 
it is unclear whether such posttransplant 
conditions infl uence the phenotypic alter-
ations in the parathyroid gland, the 
observed parathyroid-specifi c downregu-
lation of the Klotho-FGFR1 complex may 
explain why increased FGF23 exerts its 
eff ect on the kidney allograft  but fails to 
act on the parathyroid gland to suppress 
PTH secretion. 
 In this study, Krajisnik  et al. 14 also 
examined the regulation of Klotho and 
FGFR1 expression using parathyroid 
cell culture. They found that Klotho 
expression was increased by 1,25(OH) 2 D 
and decreased by FGF23 in bovine par-
athyroid cells, whereas no signifi cant 
changes were observed in hyperplastic 
cells from CKD patients. FGFR1 expres-
sion was upregulated by 1,25(OH) 2 D, 
FGF23, and phosphate even in parathy-
roid cells from CKD patients. Given that 
the alteration in expression of Klotho 
and FGFR1 may modulate the ampli-
tude of FGF23 eff ects, 2,3 these  in vitro 
data are of considerable interest; how-
ever, whether these findings can be 
extrapolated to  in vivo conditions and 
whether they play a role in the progres-
sive downregulation of the parathyroid 
Klotho-FGFR1 complex in CKD war-
rants further study. 
 The study by Krajisnik  et al. 14 is an 
important addition to the growing body 
of knowledge on the pathogenesis of 
FGF23 resistance in CKD. Although fur-
ther work is required, this study under-
scores the possibility that decreased 
kidney function plays a role in the down-
regulation of the parathyroid Klotho-
FGFR1 complex and a variety of related 
factors are involved in this regulation. In 
future, it would be important to clarify 
whether the decreased expression of the 
Klotho-FGFR1 complex has a role in the 
pathogenesis of SHPT or is only a second-
ary change accompanied by parathyroid 
hyperplasia or other metabolic alterations. 
It would also be of interest to determine 
whether upregulation of the parathyroid 
Klotho-FGFR1 complex can occur aft er 
kidney transplantation and whether this 
would lead to the attenuation of parathy-
roid hyperplasia ( Figure 1 ). Additional 
work is needed to answer these questions 
and to complete a conceptual framework 
for the role of FGF23 in the pathogenesis 
SHPT in CKD. 
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